M E Roseland1, K Schwartz2,3, J J Ruterbusch3, L Lamerato4, R Krajenta4, J Booza2, Michael S Simon5,6. 1. Wayne State University School of Medicine, Detroit, MI, USA. 2. Department of Family Medicine & Public Health Sciences, Wayne State University, Detroit, MI, USA. 3. Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, 4100 John R HW4HO, Detroit, MI, 48201, USA. 4. Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI, USA. 5. Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, 4100 John R HW4HO, Detroit, MI, 48201, USA. simonm@karmanos.org. 6. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. simonm@karmanos.org.
Abstract
BACKGROUND: African American (AA) women with breast cancer have persistently higher mortality compared to whites. We evaluated racial disparities in mortality among women with estrogen receptor (ER)/progesterone receptor (PR)-negative breast cancer. METHODS: The study population included 542 women (45% AA) diagnosed with ER/PR-negative Stage I through III breast cancer treated at the Henry Ford Health System (HFHS) between 1996 and 2005. Linked datasets from HFHS, Metropolitan Detroit Cancer Surveillance System, and the U.S. Census Bureau were used to obtain demographic, socioeconomic, and clinical information. Economic deprivation was categorized using a previously validated deprivation index, which included 5 categories based on the quintile of census tract socioeconomic deprivation. Cox proportional hazards models were used to assess the relationship between race and mortality. RESULTS: AA women were more likely to have larger tumors, have higher Charlson Comorbidity Indices (CCI), and to reside in economically deprived areas. In an unadjusted analysis, AA women demonstrated a significantly higher risk of death compared to whites [hazard ratio (HR) 1.47, 95% confidence interval (CI) 1.09-2.00]. Following adjustment for clinical factors (age, stage, CCI) and treatment (radiation and chemotherapy), AA race continued to have a significant impact on mortality (HR 1.51, CI 1.10-2.08 and HR 1.63, CI 1.20-2.21). Only after adjusting for deprivation was race no longer significant (HR 1.26, CI 0.84-1.87). CONCLUSIONS: Social determinants of health play a large role in explaining racial disparities in breast cancer outcomes, especially among women with aggressive subtypes.
BACKGROUND: African American (AA) women with breast cancer have persistently higher mortality compared to whites. We evaluated racial disparities in mortality among women with estrogen receptor (ER)/progesterone receptor (PR)-negative breast cancer. METHODS: The study population included 542 women (45% AA) diagnosed with ER/PR-negative Stage I through III breast cancer treated at the Henry Ford Health System (HFHS) between 1996 and 2005. Linked datasets from HFHS, Metropolitan Detroit Cancer Surveillance System, and the U.S. Census Bureau were used to obtain demographic, socioeconomic, and clinical information. Economic deprivation was categorized using a previously validated deprivation index, which included 5 categories based on the quintile of census tract socioeconomic deprivation. Cox proportional hazards models were used to assess the relationship between race and mortality. RESULTS: AA women were more likely to have larger tumors, have higher Charlson Comorbidity Indices (CCI), and to reside in economically deprived areas. In an unadjusted analysis, AA women demonstrated a significantly higher risk of death compared to whites [hazard ratio (HR) 1.47, 95% confidence interval (CI) 1.09-2.00]. Following adjustment for clinical factors (age, stage, CCI) and treatment (radiation and chemotherapy), AA race continued to have a significant impact on mortality (HR 1.51, CI 1.10-2.08 and HR 1.63, CI 1.20-2.21). Only after adjusting for deprivation was race no longer significant (HR 1.26, CI 0.84-1.87). CONCLUSIONS: Social determinants of health play a large role in explaining racial disparities in breast cancer outcomes, especially among women with aggressive subtypes.
Authors: M U Yood; C C Johnson; A Blount; J Abrams; E Wolman; B D McCarthy; U Raju; D S Nathanson; M Worsham; S R Wolman Journal: J Natl Cancer Inst Date: 1999-09-01 Impact factor: 13.506
Authors: Foluso O Ademuyiwa; Stephen B Edge; Deborah O Erwin; Heather Orom; Christine B Ambrosone; Willie Underwood Journal: Cancer Res Date: 2010-12-06 Impact factor: 12.701
Authors: James J Dignam; Vanja Dukic; Stewart J Anderson; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark Journal: Breast Cancer Res Treat Date: 2008-10-02 Impact factor: 4.872
Authors: Esther M John; Valerie McGuire; Allison W Kurian; Jocelyn Koo; Salma Shariff-Marco; Scarlett Lin Gomez; Iona Cheng; Theresa H M Keegan; Marilyn L Kwan; Leslie Bernstein; Cheryl Vigen; Anna H Wu Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-12-18 Impact factor: 4.090
Authors: Maura K McCall; Mary Connolly; Bethany Nugent; Yvette P Conley; Catherine M Bender; Margaret Q Rosenzweig Journal: J Cancer Educ Date: 2020-06 Impact factor: 2.037
Authors: Oluwole Adeyemi Babatunde; Whitney E Zahnd; Jan M Eberth; Andrew B Lawson; Swann Arp Adams; Eric Adjei Boakye; Melanie S Jefferson; Caitlin G Allen; John L Pearce; Hong Li; Chanita Hughes Halbert Journal: Int J Environ Res Public Health Date: 2021-11-11 Impact factor: 3.390
Authors: Michael S Simon; Sreejata Raychaudhuri; Lauren M Hamel; Louis A Penner; Kendra L Schwartz; Felicity W K Harper; Hayley S Thompson; Jason C Booza; Michele Cote; Ann G Schwartz; Susan Eggly Journal: Front Oncol Date: 2021-07-07 Impact factor: 6.244